Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Development, Human Clear all
Completed No phase listed Observational Results available

Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions

NCT04276935
View directory record Official record
Conditions
High Grade Anal Canal Squamous Intraepithelial Neoplasia, Human Immunodeficiency Virus
Interventions
Interview, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jul 21, 2026, 7:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

NCT01802918
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jul 21, 2026, 7:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of the Functional and Structural Development of the Human Neonatal Brain From 30 Wks to 45 Wks ga

NCT02170142
View directory record Official record
Conditions
Human Development
Interventions
MRI
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Weeks to 45 Weeks
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Jul 21, 2026, 7:43 PM EDT
Recruiting Phase 3 Interventional

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851
View directory record Official record
Conditions
Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Interventions
Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
2 Years to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Palo Alto, California • Sacramento, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 7:43 PM EDT
Recruiting No phase listed Observational

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

NCT05820672
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
No intervention
Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
27
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 21, 2026, 7:43 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effects of GH and Lirglutide on AgRP

NCT05681299
View directory record Official record
Conditions
Healthy, Growth Hormone Deficiency
Interventions
growth hormone and lirglutide, growth hormone, liraglutide, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 21, 2026, 7:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sensitive Periods in Human Flavor Learning

NCT01667549
View directory record Official record
Conditions
Development
Interventions
Timing of Diet and Flavor Experience
Other
Lead sponsor
Monell Chemical Senses Center
Other
Eligibility
2 Weeks to 3 Weeks
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Jul 21, 2026, 7:43 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Post-Discharge Growth and Development of Infants Who Received Targeted Fortification in the NICU

NCT04190875
View directory record Official record
Conditions
Premature Infants
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Months to 24 Months
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 21, 2026, 7:43 PM EDT
Terminated Phase 3 Interventional

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

NCT03145831
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Somavaratan
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
3 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Jul 21, 2026, 7:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Model to Evaluate Regenerative Endodontic Techniques Using Extract Human Teeth

NCT00595595
View directory record Official record
Conditions
Dental Pulp Regeneration, Dental Pulp Diseases
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
16 Years to 65 Years
Enrollment
1,080 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2012 · Synced Jul 21, 2026, 7:43 PM EDT
Recruiting No phase listed Observational

A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders

NCT06092346
View directory record Official record
Conditions
AMPD3, OMIM*102772, AMP Deaminase Deficiency, AK1, OMIM *103000, Adenylate Kinase Deficiency, AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency, TPMT, OMIM *187680, Thoipurines, Poor Metabolism of, IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11, APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency, HPRT1, OMIM *308000 Lesch-Nyhan Disease, XDH, OMIM *607633, Xanthinuria Type 1, SLC2A9, OMIM *606142 Hypouricemia, SLC22A12, OMIM *607096 Hypouricemia, PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease, PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity, AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia, ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35, ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency, PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency, ADA2, OMIM *607575,Sneddon Syndrome; VAIHS, CAD, *1140120, Developmental and Epileptic Encephalopathy, UPB1, OMIM *606673, Beta-ureidopropionase Deficiency, DPYS, OMIM *613326, Dihydropyrimidinase Deficiency, DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency, DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis), UMPS, OMIM *613891, Orotic Aciduria, NT5C3A<TAB>, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency, UNG, OMIM *191525, Hyper-IgM Syndrome 5, AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2, Purine-Pyrimidine Metabolism, Metabolic Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 100 Years
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2099
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 21, 2026, 7:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Novel Human In Vitro Sarcoidosis Model

NCT01857401
View directory record Official record
Conditions
Sarcoidosis
Interventions
No intervention, observational study only
Other
Lead sponsor
Elliott Crouser MD
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 21, 2026, 7:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of YL242 in Subjects With Advanced Solid Tumors

NCT07197827
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
YL242, YL242; Pembrolizumab, YL242; 5-FU; LV, YL242; Pembrolizumab; 5-FU
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
New Haven, Connecticut • Sarasota, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jul 21, 2026, 7:43 PM EDT
Terminated No phase listed Observational

Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma

NCT00767936
View directory record Official record
Conditions
Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers Liver, Hepatobiliary Cancers
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Jul 21, 2026, 7:43 PM EDT
Completed No phase listed Observational

Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients

NCT00551655
View directory record Official record
Conditions
Human Immunodeficiency Viruses, Kidney Failure, HIV Infections
Interventions
Not listed
Lead sponsor
AIDS Arms Inc.
Other
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Jul 21, 2026, 7:43 PM EDT
Active, not recruiting Not applicable Interventional

Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development

NCT03977259
View directory record Official record
Conditions
Preterm Birth, Breast Milk Expression, Nutrition Disorder, Infant, Brain Development Abnormality, Neurodevelopmental Disorders
Interventions
Individually targeted fortification
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
1 Day to 21 Days
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 7:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Supplemental Choline and Brain Development in Humans

NCT00678925
View directory record Official record
Conditions
Healthy
Interventions
Phosphatidylcholine, Corn oil placebo
Dietary Supplement
Lead sponsor
The Gerber Foundation
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2010 · Synced Jul 21, 2026, 7:43 PM EDT
Not listed Phase 3 Interventional

Treatment of Children With Insufficient Secretion of Growth Hormone

NCT00271518
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
growth hormone (somatropin)
Drug
Lead sponsor
LG Life Sciences
Industry
Eligibility
3 Years to 11 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2010 · Synced Jul 21, 2026, 7:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines

NCT05592223
View directory record Official record
Conditions
Tuberculosis
Interventions
BCG Vaccine USP, Isoniazid, Rifampin
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jul 21, 2026, 7:43 PM EDT
Completed Phase 3 Interventional

Synthetic Human Secretin in Children With Autism

NCT00036244
View directory record Official record
Conditions
Autism
Interventions
RG1068 (Synthetic Human Secretin)
Drug
Lead sponsor
Repligen Corporation
Industry
Eligibility
32 Months to 59 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2005 · Synced Jul 21, 2026, 7:43 PM EDT
Terminated Phase 4 Interventional Results available

Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus

NCT00260208
View directory record Official record
Conditions
Liver Transplant, Hepatitis C
Interventions
Cyclosporine A, Tacrolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Jul 21, 2026, 7:43 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Avocado Consumption, Nutrients in Human Milk, and Infant Cognitive Development

NCT06208085
View directory record Official record
Conditions
Breastfeeding, Exclusive
Interventions
Avocado
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 40 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 21, 2026, 7:43 PM EDT
Recruiting Phase 2 Interventional

Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)

NCT05355272
View directory record Official record
Conditions
Gulf War Syndrome, Adult Growth Hormone Deficiency
Interventions
Recombinant human growth hormone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 21, 2026, 7:43 PM EDT
Recruiting Phase 3 Interventional

Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.

NCT07216742
View directory record Official record
Conditions
Infertility (IVF Patients)
Interventions
hMG subcutaneous injection, Placebo
Drug
Lead sponsor
Granata Bio Corporation
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Encino, California • Norwalk, Connecticut • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 21, 2026, 7:43 PM EDT